INNOVATE BIOPHARMACEUTICALS, INC. (40)

Browse by Contract Category

Contracts

Underwriting Agreement, dated March 30, 2021, by and between 9 Meters Biopharma, Inc., Citigroup Global Markets Inc., William Blair & Company, L.L.C., and Truist Securities, Inc (Filed With SEC on April 5, 2021)
Amendment to the 2012 Omnibus Incentive Plan, dated November 27, 2020 (Filed With SEC on November 27, 2020)
Amendment No. 1, dated October 2, 2020, to the Sales Agreement between 9 Meters Biopharma and Truist Securities, Inc (Filed With SEC on October 2, 2020)
Amended and Restated Exclusive License Agreement, dated February 10, 2020, between Cedars-Sinai Medical Center and Naia Rare Diseases, Inc (Filed With SEC on August 13, 2020)
Form of RDD Pharma Ltd. Notice of Option Grant (Filed With SEC on August 13, 2020)
Agreement and Plan of Merger, dated April 30, 2020, among Innovate Biopharmaceuticals, Inc., Naia Merger Sub, Inc., Second Naia Merger Sub, LLC, and Naia Rare Diseases, Inc (Filed With SEC on May 4, 2020)
Underwriting Agreement, dated December 11, 2020, by and between 9 Meters Biopharma, Inc., William Blair & Company, L.L.C., and Truist Securities, Inc., as representatives of the... (Filed With SEC on December 15, 2020)
Amended and Restated License Agreement, dated May 1, 2020, between Amunix Pharmaceuticals, Inc. and Naia Rare Diseases, Inc (Filed With SEC on August 13, 2020)
Side Letter, dated May 1, 20202, between Amunix Pharmaceuticals, Inc. and Naia Rare Diseases, Inc (Filed With SEC on August 13, 2020)
Second Amended and Restated License Agreement, dated May 1, 2020, between Amunix Pharmaceuticals, Inc. and Naia Rare Diseases, Inc (Filed With SEC on August 13, 2020)
Sales Agreement, dated as of July 22, 2020, between 9 Meters Biopharma, Inc. and SunTrust Robinson Humphrey, Inc (Filed With SEC on July 22, 2020)
9 Meters Biopharma, Inc. 2012 Omnibus Incentive Plan, as amended (Filed With SEC on June 30, 2020)
Form of Company Support Agreement by and among Innovate Biopharmaceuticals, Inc. and RDD Pharma Ltd (Filed With SEC on May 4, 2020)
Employment Agreement, dated April 30, 2020, between Innovate Biopharmaceuticals, Inc. and John Temperato (Filed With SEC on May 4, 2020)
Separation Agreement, dated April 30, 2020, between Innovate Biopharmaceuticals, Inc. and Jay Madan (Filed With SEC on May 4, 2020)
Separation Agreement, dated April 30, 2020, between Innovate Biopharmaceuticals, Inc. and Sandeep Laumas (Filed With SEC on May 4, 2020)
Form of Series A Convertible Preferred Stock Warrant (Filed With SEC on May 4, 2020)
Securities Purchase Agreement, dated April 29, 2020, between Innovate Biopharmaceuticals, Inc. and the investors named therein (Filed With SEC on May 4, 2020)
Registration Rights Agreement, dated April 29, 2020, between Innovate Biopharmaceuticals, Inc. and the investors named therein (Filed With SEC on May 4, 2020)
Executive Employment Agreement dated February 15, 2019, by and between the Company and Patrick H. Griffin, M.D (Filed With SEC on March 20, 2020)
Description of the Companys Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 (Filed With SEC on March 20, 2020)
Form of Amendment to Short-term Common Stock Purchase Warrant, dated February 6, 2020 (Filed With SEC on February 12, 2020)
Note issued to Atlas Sciences, LLC (Filed With SEC on January 10, 2020)
Note Purchase Agreement, dated January 10, 2020, by and between the Company and Atlas Sciences, LLC (Filed With SEC on January 10, 2020)
Form of Exchange Agreement (Filed With SEC on December 20, 2019)
Amendment No. 1 to Agreement and Plan of Merger and Reorganization, dated as of December 17, 2019, by and between Innovate Biopharmaceuticals, Inc., INNT Merger Sub 1 Ltd., RDD... (Filed With SEC on December 17, 2019)
Executive Employment Agreement, dated June 22, 2019, between the Company and Edward J. Sitar (Filed With SEC on June 27, 2019)
Form of Placement Agent Warrant (Filed With SEC on May 1, 2019)
Form of Securities Purchase Agreement, dated April 29, 2019, by and among the Company and the purchasers party thereto (Filed With SEC on May 1, 2019)
Engagement Letter, dated April 26, 2019, between the Company and H.C. Wainwright & Co., LLC (Filed With SEC on May 1, 2019)
Form of Warrant (Filed With SEC on May 1, 2019)
Amendment, dated April 25, 2019, to Securities Purchase Agreement, dated as of March 17, 2019, by and between the Company and the Purchasers party thereto (Filed With SEC on April 26, 2019)
Separation Agreement, dated February 19, 2019, by and between the Company and Christopher Prior (Filed With SEC on March 18, 2019)
Form of Long-Term Warrant (included in Exhibit 10.1) (Filed With SEC on March 18, 2019)
Separation Agreement, dated November 16, 2018, by and between the Company and June Almenoff (Filed With SEC on March 18, 2019)
Consulting Agreement, dated February 19, 2019, by and between the Company and Christopher Prior (Filed With SEC on March 18, 2019)
First Amendment, dated February 19, 2019, to Amended and Restated Executive Employment Agreement, dated March 11, 2018, by and between the Company and Sandeep Laumas (Filed With SEC on March 18, 2019)
Note Purchase Agreement, dated March 8, 2019, by and between the Company and Atlas Sciences, LLC (Filed With SEC on March 13, 2019)
Note issued to Atlas Sciences, LLC (Filed With SEC on March 13, 2019)
Option to Purchase Senior Convertible Note, by and between the Company and Gustavia Capital Partners LLC and/or its affiliates dated as of January 7, 2019 (Filed With SEC on January 11, 2019)